OBJECTIVES: This study in patients with chronic obstructive pulmonary disease (COPD) investigated whether acute exacerbation of COPD (AECOPD) and clinically stable COPD (CSCOPD) are associated with changes in circulating insulin-like growth factor-1 (IGF-1) and Creactive protein (CRP) concentrations, and whether changes in IGF-1 and CRP levels are related to changes in the indicators of malnutrition and muscle wasting. METHODS: A total of 61 patients with AECOPD, 43 patients with CSCOPD and 20 healthy age-matched controls were included in the study. Circulating IGF-1 and CRP levels, together with erythrocyte sedimentation rate and indicators of malnutrition and muscle wasting, were measured in all the study participants. RESULTS: Circulating IGF-1 levels were significantly lower and CRP levels significantly higher in COPD patients than in controls. In addition, IGF-1 levels were significantly lower and CRP levels significantly higher in AECOPD patients than in CSCOPD patients. In COPD patients, indicators of malnutrition and muscle wasting (weight, body mass index, thigh circumference and albumin level) were significantly positively correlated with logIGF-1; thigh circumference and albumin level were significantly inversely correlated with logCRP. CONCLUSION: Circulating IGF-1 and CRP levels may have potential as indicators of exacerbation, malnutrition and muscle wasting in patients with COPD.
Introduction
The multisystemic consequences of chronic obstructive pulmonary disease (COPD) include a high susceptibility to exacerbation of clinical symptoms, severely impaired functional capacity, poor health status and a low quality of life. Endocrine disorder, systemic inflammation, oxidative stress and hypoxia may contribute to the multisystemic effects of COPD. 1 Endocrine disorder and systemic inflammation can promote a hypermetabolic state and an overall catabolic/anabolic imbalance, leading to the depletion of endogenous energy stores and, eventually, to M Ye, H Yu, W Yu et al. Circulating IGF-1 and C-reactive protein in COPD degradation of structural tissue. 2, 3 Weight loss due to tissue wasting is frequent in COPD and may ultimately lead to cachexia, a serious comorbidity associated with an advanced disease state. 4 Previous studies have shown that systemic biomarkers present during acute exacerbation of COPD (AECOPD) are different to those observed during other stages of the disease. 5 However, systemic biomarkers that can be used to diagnose and evaluate AECOPD have not yet been identified.
Insulin-like growth factor-1 (IGF-1) is released systemically in response to autocrine/paracrine signalling and acts by binding to and activating the IGF-1 receptor, which triggers growth-promoting and antiapoptotic pathways. Moreover, IGF-1 is also thought to improve nitrogen balance and have anabolic effects. Some studies have suggested that inappropriately decreased IGF-1 levels occur in AECOPD and clinically stable COPD (CSCOPD). 5, 6 It has been shown that C-reactive protein (CRP) is a sensitive biomarker of acute inflammation 7 and an indicator of prognosis in end-stage respiratory disease. 8 In COPD, circulating CRP levels are associated with malnutrition, weight loss, increased dyspnoea index and reduced quality of life, 9, 10 and are inversely correlated with exercise endurance and airway obstruction. 11 The present study examined: clinical characteristics, muscle wasting and indicators of malnutrition in patients with COPD; whether AECOPD and CSCOPD are associated with changes in circulating IGF-1 and CRP concentrations; and whether changes in IGF-1 and CRP levels are related to changes in the indicators of malnutrition and muscle wasting.
Patients and methods

PATIENTS
Patients with AECOPD or CSCOPD from the First Affiliated Hospital of Shantou University Medical College, Shantou, China, were recruited sequentially to the study between January 2010 and October 2011. Diagnosis of COPD was made on the basis of history, physical examination and pulmonary function tests using the guidelines of the Global Initiative for Chronic Obstructive Lung Disease; 1 thus all COPD patients had a ratio of forced expiratory volume in 1 s (FEV 1 ) to forced vital capacity (FVC) of < 70% and FEV 1 < 80% of the predicted value in response to inhaled bronchodilators. AECOPD was defined as the presence of one of the following criteria in a patient with COPD: (i) recently increased cough or dyspnoea, (ii) increased sputum volume, or (iii) sputum purulence. CSCOPD was defined as clinically stable COPD without signs of acute exacerbation 1 in patients who had not required hospital admission or adjusted treatment within the prior 3 months. Patients with CSCOPD were followed up as outpatients, whereas patients with AECOPD were admitted to hospital within 3 days of the onset of the exacerbation.
Patients with diabetes mellitus, chronic heart failure, pulmonary tuberculosis, asthma, cancer, thyroid disease and liver disease were excluded from the study. All patients receiving intravenous or oral corticosteroid treatment were also excluded. Patients taking low doses of inhaled corticosteroids, such as daily doses of 160 -320 µg budesonide or 500 -1000 µg fluticasone, were included.
Age-matched healthy subjects were recruited from the local population of Shantou, China, to act as controls. These subjects had no medical history or current illnesses and showed no symptoms or signs of infection at the time of the study; physical examination, blood counts, blood M Ye, H Yu, W Yu et al. Circulating IGF-1 and C-reactive protein in COPD biochemical indexes and lung function tests were all normal.
Height, weight, chest circumference and thigh circumference were measured and body mass index (BMI) was calculated in all study participants. Patients with COPD were divided according to weight into two groups using the World Health Organization Asia-Pacific guidelines: 12 cachexic (BMI < 18.5 kg/m 2 ) and noncachexic (BMI ≥ 18.5 kg/m 2 ).
All study participants provided written informed consent. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Shantou University Medical College.
LUNG FUNCTION TESTS
Lung function tests (FEV 1 , FVC, FEV 1 /FVC ratio) were performed using a portable spirometer (Micro Medical™ MicroLab, CareFusion UK, Chatham, UK) after administration of an inhaled bronchodilator (200 µg salbutamol sulphate). All values obtained were expressed as a percentage of the predicted value. Lung function tests in patients with AECOPD were performed during the remission stage, approximately 3 -7 days after admission.
IGF-1 AND INFLAMMATORY AND MALNUTRITIONAL MARKERS
Blood samples were drawn from an antecubital vein in the morning between 07.00 h and 08.00 h, after a fasting period of ≥ 8 h. In patients with AECOPD, blood samples were taken before the administration of corticosteroid or antibiotic treatment. Serum was separated from blood cells by centrifugation at 1000 g for 20 min. All samples were stored at -30°C until analysed.
Levels of IGF-1 were measured using an enzyme-linked immunosorbent assay kit according to the manufacturer's instructions (Uscn Life Science & Technology, Wuhan, China); the detection limit was 3.2 ng/ml. CRP levels were assessed using a Beckman IMMAGE ® 800 automated analyser (Beckman Coulter, Brea, CA, USA), with a lowest detection limit of 0.1 mg/l. Levels of the malnutritional markers creatinine, blood urea nitrogen and albumin were measured using a Beckman DXC800 automated analyser (Beckman Coulter). Erythrocyte sedimentation rate (ESR) was measured using the classical Westergren method.
STATISTICAL ANALYSES
Data for parameters with a normal distribution were expressed as the mean ± SD and compared using analysis of variance. Data for parameters that did not have a normal distribution were expressed as the median with 25th and 75th percentiles, and compared using the nonparametric Mann-Whitney U-test. Logarithmic values for IGF-1 and CRP (logIGF-1 and logCRP, respectively) were calculated from the absolute values in order to produce a normal distribution. Differences in logIGF-1 and logCRP in COPD patients, stratified according to weight, were compared using the independent samples ttest. Correlations between parameters were calculated using Pearson's correlation coefficient test. A P-value < 0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS ® software version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® .
Results
A total of 104 patients with COPD were included in the study. Of these, 43 patients (40 males, three females) had CSCOPD and 61 patients (55 males, six females) had AECOPD. The control group consisted of 20 healthy subjects (15 males, five females). Demographic and anthropometric M Ye, H Yu, W Yu et al. Circulating IGF-1 and C-reactive protein in COPD characteristics and lung function data for all the study participants are given in Table 1 . There were no significant differences in these parameters between patients with AECOPD and those with CSCOPD.
CIRCULATING IGF-1 LEVEL
The circulating IGF-1 level in patients with COPD was significantly lower than that in healthy controls (P < 0.001; Table 2 ). In addition, the IGF-1 level in AECOPD patients was significantly lower than that in CSCOPD patients (P < 0.001). Similar results were seen for logIGF-1 levels.
INFLAMMATORY AND MALNUTRITIONAL MARKERS
Patients with COPD had significantly higher levels of CRP (P = 0.001) and logCRP (P < 0.001) and significantly lower levels of albumin (P < 0.001) compared with healthy controls (Table 2 ). There were no statistically significant differences in levels of creatinine and blood urea nitrogen or in ESR between the COPD patients and controls.
There were no statistically significant differences in CRP, logCRP and ESR levels between patients with CSCOPD and healthy controls, whereas patients with AECOPD had significantly higher CRP, logCRP and ESR levels compared with healthy controls (P < 0.001, P < 0.001 and P = 0.019, respectively) and patients with CSCOPD (P < 0.001, P < 0.001 and P = 0.01, respectively) ( Table 2 ).
BMI
Of the 104 patients with COPD, 30 were cachexic (BMI < 18.5 kg/m 2 ) and 74 were noncachexic (BMI ≥ 18.5 kg/m 2 ). LogIGF-1 and logCRP values in patients with COPD stratified according to BMI are given in Table  3 . Cachexic patients with COPD had a significantly lower logIGF-1 compared with noncachexic patients with COPD (P = 0.024).
There was no statistically significant difference in logCRP between the cachexic and the noncachexic patients with COPD.
CORRELATION ANALYSES
In patients with COPD, logIGF-1 was significantly positively correlated with weight (r = 0.225, P < 0.05), BMI (r = 0.218, P < 0.05), thigh circumference (r = 0.412, P < 0.001) and albumin (r = 0.238, P = 0.015) and significantly inversely correlated with logCRP (r = -0.339, P < 0.001). LogCRP was significantly inversely correlated with thigh circumference (r = -0.212, P < 0.05) and albumin (r = -0.289, P = 0.013).
Discussion
The present study examined circulating IGF-1 and CRP concentrations in patients with AECOPD and CSCOPD, and investigated the relationship between these levels and malnutritional markers. Changes in circulating IGF-1 and CRP concentrations may be considered to be a reflection of the exacerbated endocrine disorder and systemic inflammation observed in AECOPD. In the present study, patients with COPD had significantly higher levels of CRP and significantly lower levels of IGF-1 and albumin compared with healthy controls. When subdivided according to the presence of acute exacerbation, these significant differences in IGF-1, CRP and albumin were still seen for both AECOPD and CSCOPD patients compared with controls; however, patients with AECOPD had significantly lower levels of IGF-1 and significantly higher levels of CRP than those with CSCOPD. Patients with AECOPD also had a significantly higher ESR than those with CSCOPD. In COPD patients, logIGF-1 was significantly positively correlated with weight, BMI, thigh circumference, albumin and CRP, and logCRP was significantly 
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inversely correlated with thigh circumference and albumin. LogIGF-1 was significantly lower in cachexic COPD patients compared with noncachexic weight patients.
The decreased IGF-1 concentrations seen in both the CSCOPD and AECOPD subgroups in the present study are consistent with the results of other investigations. Spruit et al. 13 and Kythreotis et al. 5 reported that circulating IGF-1 concentrations were lower in AECOPD patients compared with healthy subjects. In a study by Coşkun et al., 6 circulating IGF-1 levels were decreased in stable COPD patients compared with healthy controls and were related to the severity of disease. It has been previously shown that the bioavailability and effects of IGF-1 are affected by IGF-binding proteins (IGFBPs). 14 In addition, formation of a ternary complex consisting of IGF-1, IGFBPs and an acidlabile subunit (ALS) restricts IGF-1 to the circulation and prolongs its half-life. 5, 15 Systemic inflammation increases IGFBP-1 and IGFBP-4 and decreases ALS synthesis. 16 Thus, elevated levels of these IGFBPs may lead to reduced free IGF-1 concentrations. In addition, ALS has a suppressive effect on IGF-1 by decreasing its half-life. 14, 15 COPD patients in a state of malnutrition and anorexia may have decreased IGF-1 and ALS synthesis; systemic inflammation stimulates the synthesis of acute-phase proteins during AECOPD, leading to depletion of the specific amino acids required to synthesize IGF-1 and ALS and, ultimately, resulting in decreased levels of free IGF-1 and COPD exacerbation. 16, 17 Previous studies have indicated that intravenous or oral corticosteroids may affect circulating IGF-1 levels. This effect is thought to be associated with dosage and time course, but it remains controversial as to whether circulating IGF-1 levels are increased or decreased in response to corticosteroids. 18 -21 A long period of systemic steroid therapy may influence circulating IGF-1 levels by suppressing the growth hormone-IGF axis, 22 however, corticosteroids may allow shortterm recovery of the levels of circulating IGF-1 by abating inflammation. 18 Patients receiving intravenous or oral corticosteroid therapy were excluded from the present study in order to eliminate these effects.
Shin et al. 23 found that age and gender may affect serum IGF-1. In the present study, there were no statistically significant differences in weight or age between the CSCOPD and AECOPD groups, therefore the reduction in circulating IGF-1 levels in the patients with AECOPD appears to be related to COPD exacerbation. Furthermore, the increase in IGF-1 levels in CSCOPD patients compared with AECOPD patients suggests that systemic inflammation and endocrine disorder may be ameliorated during this clinically stable stage. Further studies are 
3: Log insulin-like growth factor-1 (logIGF-1) and log C-reactive protein (logCRP) in patients with chronic obstructive pulmonary disease, with body mass index (BMI) < 18.5 kg/m 2 (cachexic) or BMI ≥ 18.5 kg/m 2 (noncachexic)
Cachexic
Noncachexic Statistical Parameter (n = 30) (n = 74) significance
LogIGF-1 2.01 ± 0.13 2.06 ± 0.09 P = 0.024 LogCRP 0.92 ± 0.51 1.00 ± 0.60 NS Data presented as mean ± SD; comparisons between the groups used the independent samples t-test. NS, no statistically significant between-group differences (P ≥ 0.05).
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needed to elucidate the reliability and reference range of IGF-1 levels during COPD exacerbation.
In the present study, circulating IGF-1 levels were significantly associated with weight, BMI, thigh circumference, albumin and logCRP levels. Malnutrition is prevalent in patients with COPD 24 and may act synergistically with the depletion of specific amino acids during COPD exacerbation to play a role in the decline of circulating IGF-1 and albumin levels. In the present study, logIGF-1 was related to BMI in COPD patients, with cachexic patients showing decreased logIGF-1. Low levels of anabolic hormones could act synergistically with catabolic imbalance and play a role in weight loss. This suggests that decreased IGF-1 levels in COPD patients may be an indicator of malnutrition.
In a study by Spruit et al., 13 circulating IGF-1 levels were positively correlated with peripheral muscle strength. In addition, Crul et al. 25 have shown that expression of muscle IGF-1 RNA decreased in vastus lateralis muscle biopsies in AECOPD and was related to muscle weakness. In the present study, only circulating IGF-1 was measured; paracrine/autocrine IGF-1 production in the peripheral muscles was not investigated. Thigh circumference was found, however, to be significantly less in COPD patients compared with healthy controls and was positively correlated with circulating IGF-1 levels. These results seem to suggest that circulating IGF-1 levels may play a role in thigh muscle wasting. Patients with COPD demonstrate decreased physical activity levels and disuse may be the main mechanism causing decreased muscle IGF-1 levels in this population. 25 Based on this and prior studies, we suggest that the decreased level of free circulating IGF-1 entering the musculature by transmembrane transport acts synergistically with reduced paracrine/ autocrine IGF-1 production, leading to thigh muscle wasting and dysfunction in COPD patients.
C-reactive protein is a sensitive biomarker produced in response to acute inflammation, and is regarded as an indicator of prognosis and mortality in COPD. 7, 8, 26 Piehl-Aulin et al. 27 reported that high-sensitivity CRP levels were increased in skeletal muscle in COPD in the absence of any clinical signs of disease exacerbation, evidence of skeletal muscle inflammation or hormonal changes. This suggests that systemic inflammation is involved in muscle wasting and impairment at an early stage. In the present study, levels of circulating CRP were elevated in COPD patients, particularly those with AECOPD. These results are in keeping with studies by Spruit et al. 13 and Hurst et al. 28 who reported increased levels of circulating CRP in COPD patients. In the present study, however, the difference in circulating CRP levels between CSCOPD patients and healthy controls was not statistically significant. This differs from the results reported by Karadag et al. 9 A reason for this difference might be the inclusion in the present study of patients receiving inhaled corticosteroid treatment, which has been shown to cause a decrease in local or systemic inflammation. 11, 29 In addition, the sample size in the present study may have been too small to show a statistically significant difference.
de Torres et al. 10 proposed that circulating CRP levels in stable COPD patients correlated best with the 6-min walking distance. Maltais 30 hypothesized that muscle wasting and impairment resulted from systemic inflammation. In the present study there was a strong correlation between logCRP levels and thigh circumference, albumin levels and logIGF-1 in COPD patients: these are parameters that reflect M Ye, H Yu, W Yu et al. Circulating IGF-1 and C-reactive protein in COPD the degree of malnutrition, muscle wasting and endocrine disorder. The elevated levels of CRP in COPD patients suggest that systemic inflammation stimulates CRP synthesis and results in a lack of amino acids and muscle fibre proteolysis. A reduction in thigh circumference in COPD patients may result from chronic hypoxia, hypermetabolism, malnutrition, skeletal muscle fibre-type shifting, systemic inflammation and endocrine disorder acting synergistically to decrease muscular mass. 4, 17 It has not yet been conclusively demonstrated that systemic inflammation affects COPD. Several studies have reported that various potential inflammationmediated mechanisms may influence the process of COPD. 31, 32 Local pulmonary inflammation in COPD patients may lead to systemic inflammation, as increased inflammatory media and oxidants in the lungs enter the circulation and interact with peripheral inflammatory cells. Activated marrow and liver cells produce and release more inflammatory mediators, and these proinflammatory mediators can induce and exacerbate systemic and local inflammation in COPD. In the present study there was an inverse relationship between logCRP and logIGF-1. These findings suggest that systemic inflammation may decrease circulating IGF-1 levels in COPD patients, especially during acute exacerbations. Persistent systemic inflammation, in conjunction with endocrine disorder, can result in anabolic dysfunction and may play a role in muscle wasting and weight loss.
There are a number of limitations to the present study. First, several patients were treated with a standard protocol of medication consisting of inhaled corticosteroids. Some studies have shown, however, that inhaled corticosteroids act mainly on the pulmonary system to decrease local inflammation but have little systemic effect. 19 -21 In addition, the proportion of inhaled corticosteroids that is absorbed into the circulation via the gastrointestinal tract or lungs undergoes considerable metabolism. A variety of factors -including the inhaler device used, particle size, deposition site, and the pharmacokinetic and physicochemical properties of the drug -determine the extent of absorption into the circulation. 19 -21 In the present study, patients received low doses of inhaled corticosteroids, such as 160 -320 µg budesonide or 500 -1000 µg fluticasone, daily.
Secondly, it has been reported that reduction in lung function is commensurate with the onset of symptoms in AECOPD, with approximately 93% of AECOPD patients recovering to baseline lung function after 3 months. 33 In the present study, therefore, patients with CSCOPD were defined as those who had not required hospital admission or adjusted treatment within the prior 3 months; lung function data only served as criteria for the diagnosis of COPD but were not used to classify the COPD patients further.
Thirdly, CRP may not adequately reflect all forms of systemic inflammation, in particular inflammation induced by bacteria and viruses. 9 Some studies have, however, suggested that CRP is a valid biomarker of low-grade systemic inflammation in COPD. 7, 9 In summary, the present study demonstrated significantly decreased circulating IGF-1 levels and significantly increased CRP levels in COPD. These differences were accentuated in AECOPD. It is concluded that circulating IGF-1 and CRP levels might be regarded as valid biomarkers of AECOPD and could be helpful for predicting the evolution and prognosis of AECOPD patients. In addition, in COPD patients, IGF-1 levels positively correlated with weight, BMI, thigh circumference and albumin, and CRP levels inversely correlated with thigh circumference and albumin. Circulating IGF-1 and CRP levels may, therefore, also have potential as indicators of malnutrition and muscle wasting in COPD patients.
